Phase I trial for the Prevention of Cytokine Release Syndrome (CRS) with Cyclosporine in Patients with Moderate COVID-19

Site Image

Study Overview

Recruiting hospitalized patients within Penn Medicine

The purpose of this study is to determine if it is safe to take Cyclosporine for up to two weeks in patients who have COVID-19 infection. The reason this is important for people afflicted with the COVID-19 virus is that an over active immune system leading to cytokine release syndrome is thought to cause death in some patients. The long-term goal of this research is to learn if Cyclosporine can prevent or decrease the risk of cytokine release syndrome. 

Study Description

The research study is being conducted to learn why some people get very sick from COVID-19. This study will test whether some people make more immune responses in the blood, and that this is an overreaction to the virus. This reaction can actually lead to harm and cause more damage in the lungs, leading to more difficulty breathing. By volunteering to be on this study, you would be treated with Cyclosporine, a drug that suppresses the immune response. You would take the drug for up to 2 weeks, or until you are discharged from the hospital, whichever comes first. 

  • Study Identifier: 842998

Recruitment Status

Closed
Volunteer Sign up

Volunteer Sign-up

Participate in medical studies to develop new diagnostic and clinical treatments and improve current standards of care.

Sign Up Now!

If you need assistance finding a non-cancer study or if you have any questions, please email psom-ocr@pobox.upenn.edu